These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 28278708)

  • 21. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
    Gaballa MR; Besa EC
    Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".
    Rasmussen B; Göhring G; Bernard E; Nilsson L; Tobiasson M; Jädersten M; Garelius H; Dybedal I; Grønbaek K; Ejerblad E; Lorenz F; Flogegård M; Marcher CW; Öster Fernström A; Cavelier L; Papaemmanuil E; Ebeling F; Kittang AO; Nørgaard JM; Saft L; Möllgård L; Hellström-Lindberg E
    Leukemia; 2022 May; 36(5):1436-1439. PubMed ID: 35277655
    [No Abstract]   [Full Text] [Related]  

  • 23. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
    Heise C; Carter T; Schafer P; Chopra R
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q).
    Pardanani A; Patnaik MM; Lasho TL; Mai M; Knudson RA; Finke C; Ketterling RP; McClure RF; Tefferi A
    Leukemia; 2010 Jul; 24(7):1370-2. PubMed ID: 20485375
    [No Abstract]   [Full Text] [Related]  

  • 25. JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones.
    Sokol L; Caceres G; Rocha K; Stockero KJ; Dewald DW; List AF
    Leuk Res; 2010 Jun; 34(6):821-3. PubMed ID: 19819015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation.
    Ohanian M; Bueso-Ramos C; Ok CY; Lin P; Patel K; Alattar ML; Khoury JD; Rozovski U; Estrov Z; Huh YO; Cortes J; Abruzzo LV
    Cancer Genet; 2015 Nov; 208(11):571-4. PubMed ID: 26382622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.
    Platzbecker U; Braulke F; Kündgen A; Götze K; Bug G; Schönefeldt C; Shirneshan K; Röllig C; Bornhäuser M; Naumann R; Neesen J; Giagounidis A; Hofmann WK; Ehninger G; Germing U; Haase D; Wermke M
    Leukemia; 2013 Jun; 27(6):1403-7. PubMed ID: 23354011
    [No Abstract]   [Full Text] [Related]  

  • 28. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.
    Chen Y; Kantarjian H; Estrov Z; Faderl S; Ravandi F; Rey K; Cortes J; Borthakur G
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):341-4. PubMed ID: 22579233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrent genetic defects on chromosome 5q in myeloid neoplasms.
    Hosono N; Makishima H; Mahfouz R; Przychodzen B; Yoshida K; Jerez A; LaFramboise T; Polprasert C; Clemente MJ; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Sanada M; Cui E; Verma AK; McDevitt MA; List AF; Saunthararajah Y; Sekeres MA; Boultwood J; Ogawa S; Maciejewski JP
    Oncotarget; 2017 Jan; 8(4):6483-6495. PubMed ID: 28031539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).
    Fenaux P; Giagounidis A; Selleslag D; Beyne-Rauzy O; Mittelman M; Muus P; Nimer SD; Hellström-Lindberg E; Powell BL; Guerci-Bresler A; Sekeres MA; Deeg HJ; Del Cañizo C; Greenberg PL; Shammo JM; Skikne B; Yu X; List AF
    J Hematol Oncol; 2017 Jun; 10(1):131. PubMed ID: 28651604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
    Cerqui E; Pelizzari A; Schieppati F; Borlenghi E; Pagani C; Bellotti D; Lamorgese C; Boiocchi L; Sottini A; Imberti L; Rossi G
    Leuk Lymphoma; 2015; 56(11):3129-34. PubMed ID: 25811676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rare tetraploidy with large 5q deletion in acute myeloid leukemia with myelodysplasia-related changes (AML-MRC).
    Jarosova M; Nedomova R; Hubacek J; Holzerova M; Mickova P; Katrincsakova B; Pikalova Z; Papajik T; Indrak K
    Leuk Res; 2012 Apr; 36(4):e68-70. PubMed ID: 22284693
    [No Abstract]   [Full Text] [Related]  

  • 33. Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
    Arcioni F; Roncadori A; Di Battista V; Tura S; Covezzoli A; Cundari S; Mecucci C;
    Eur J Haematol; 2018 Jul; 101(1):78-85. PubMed ID: 29569278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients.
    Patnaik MM; Lasho TL; Finke CM; Knudson RA; Ketterling RP; Chen D; Hoyer JD; Hanson CA; Tefferi A
    Am J Hematol; 2011 May; 86(5):393-8. PubMed ID: 21523797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.
    Mährle T; Akyüz N; Fuchs P; Bonzanni N; Simnica D; Germing U; Asemissen AM; Jann JC; Nolte F; Hofmann WK; Nowak D; Binder M
    Haematologica; 2019 Jul; 104(7):1355-1364. PubMed ID: 30655375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
    Sánchez-García J; Del Cañizo C; Lorenzo I; Nomdedeu B; Luño E; de Paz R; Xicoy B; Valcárcel D; Brunet S; Marco-Betes V; García-Pintos M; Osorio S; Tormo M; Bailén A; Cerveró C; Ramos F; Diez-Campelo M; Such E; Arrizabalaga B; Azaceta G; Bargay J; Arilla MJ; Falantes J; Serrano-López J; Sanz GF;
    Br J Haematol; 2014 Jul; 166(2):189-201. PubMed ID: 24716538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.
    Giagounidis AA
    Semin Hematol; 2012 Oct; 49(4):312-22. PubMed ID: 23079061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A decade of progress in myelodysplastic syndrome with chromosome 5q deletion.
    List A; Ebert BL; Fenaux P
    Leukemia; 2018 Jul; 32(7):1493-1499. PubMed ID: 29445113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Precursors of acute leukemia: myelodysplastic syndromes and myeloproliferative neoplasms].
    Kreipe HH
    Pathologe; 2011 Nov; 32 Suppl 2():271-6. PubMed ID: 22033685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concurrent
    Tremblay-LeMay R; Chang H
    Blood; 2018 Jul; 132(1):112. PubMed ID: 29976782
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.